Trehalose pathway as an antifungal target.

Journal Article (Journal Article;Review)

With an increasing immunocompromised population which is linked to invasive fungal infections, it is clear that our present 3 classes of antifungal agents may not be sufficient to provide optimal management to these fragile patients. Furthermore, with widespread use of antifungal agents, drug-resistant fungal infections are on the rise. Therefore, there is some urgency to develop the antifungal pipeline with the goal of new antifungal agent discovery. In this review, a simple metabolic pathway, which forms the disaccharide, trehalose, will be characterized and its potential as a focus for antifungal target(s) explained. It possesses several important features for development of antifungal agents. First, it appears to have fungicidal characteristics and second, it is broad spectrum with importance across both ascomycete and basidiomycete species. Finally, this pathway is not found in mammals so theoretically specific inhibitors of the trehalose pathway and its enzymes in fungi should be relatively non-toxic for mammals. The trehalose pathway and its critical enzymes are now in a position to have directed antifungal discovery initiated in order to find a new class of antifungal drugs.

Full Text

Duke Authors

Cited Authors

  • Perfect, JR; Tenor, JL; Miao, Y; Brennan, RG

Published Date

  • February 17, 2017

Published In

Volume / Issue

  • 8 / 2

Start / End Page

  • 143 - 149

PubMed ID

  • 27248439

Pubmed Central ID

  • PMC5383216

Electronic International Standard Serial Number (EISSN)

  • 2150-5608

Digital Object Identifier (DOI)

  • 10.1080/21505594.2016.1195529


  • eng

Conference Location

  • United States